Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Degron Partners Molecular Glue Degraders with Takeda in $1.2 Billion Deal

publication date: May 23, 2024

Shanghai Degron Therapeutics will use its molecular glue-based targeted protein degradation drug discovery platform to identify multiple targets in oncology, neuroscience, and inflammation for Japan’s Takeda. The Chinese company will receive an upfront payment and is eligible to receive potential milestone payments that could total $1.2 billion. Degron will apply its GlueXplorer platform to identify molecular glue degraders for therapeutic targets selected by Takeda. Upon reaching a specified stage of advancement, the projects will be sent to Takeda for further development and commercialization. Degron will also receive royalty payments on sales, and Takeda will make an investment of unspecified size in Degron. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital